Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE

Original Publication: [London] : BioMed Central, c2002-

Tumor Microenvironment*/genetics ; Single-Cell Analysis*/methods ; Pancreatic Neoplasms*/genetics ; Pancreatic Neoplasms*/pathology ; Pancreatic Neoplasms*/metabolism; Humans ; Carcinoma, Pancreatic Ductal/pathology ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/metabolism ; Animals ; Biomarkers, Tumor ; Genomics/methods ; Gene Expression Regulation, Neoplastic ; Multiomics

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis and limited therapeutic options. Research on the tumor microenvironment (TME) of PDAC has propelled the development of immunotherapeutic and targeted therapeutic strategies with a promising future. The emergence of single-cell sequencing and mass spectrometry technologies, coupled with spatial omics, has collectively revealed the heterogeneity of the TME from a multiomics perspective, outlined the development trajectories of cell lineages, and revealed important functions of previously underrated myeloid cells and tumor stroma cells. Concurrently, these findings necessitated more refined annotations of biological functions at the cell cluster or single-cell level. Precise identification of all cell clusters is urgently needed to determine whether they have been investigated adequately and to identify target cell clusters with antitumor potential, design compatible treatment strategies, and determine treatment resistance. Here, we summarize recent research on the PDAC TME at the single-cell multiomics level, with an unbiased focus on the functions and potential classification bases of every cellular component within the TME, and look forward to the prospects of integrating single-cell multiomics data and retrospectively reusing bulk sequencing data, hoping to provide new insights into the PDAC TME.
(© 2024. The Author(s).)

Cancers (Basel). 2019 Mar 07;11(3):. (PMID: 30866547)
Nat Genet. 2023 Dec;55(12):2224-2234. (PMID: 37957340)
Nat Biomed Eng. 2021 Nov;5(11):1246-1260. (PMID: 34083764)
Nucleic Acids Res. 2021 May 21;49(9):e50. (PMID: 33544846)
Clin Transl Med. 2024 Mar;14(3):e1595. (PMID: 38426634)
Cell Death Differ. 2023 May;30(5):1155-1165. (PMID: 36828915)
Nat Immunol. 2019 Feb;20(2):163-172. (PMID: 30643263)
J Immunother Cancer. 2022 Dec;10(12):. (PMID: 36600557)
Nat Rev Genet. 2021 Oct;22(10):627-644. (PMID: 34145435)
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):351-8. (PMID: 11773639)
Genes Dev. 2023 Sep 1;37(17-18):818-828. (PMID: 37775182)
Nat Methods. 2024 Jun;21(6):930-933. (PMID: 38789649)
Cancer Cell. 2024 Jan 8;42(1):101-118.e11. (PMID: 38157863)
Nature. 2022 Dec;612(7938):141-147. (PMID: 36352227)
Cancer Discov. 2019 Feb;9(2):282-301. (PMID: 30366930)
Science. 2024 Jan 12;383(6679):eadf6493. (PMID: 38207030)
Int J Surg. 2024 Feb 01;110(2):740-749. (PMID: 38085810)
Cancer Res. 2017 Nov 1;77(21):e108-e110. (PMID: 29092952)
Nat Med. 2023 Dec;29(12):3033-3043. (PMID: 37985692)
Cell. 2021 Dec 9;184(25):6081-6100.e26. (PMID: 34861191)
Nat Cancer. 2023 Apr;4(4):454-467. (PMID: 36959420)
Front Oncol. 2022 Sep 16;12:929950. (PMID: 36185212)
Acta Pharm Sin B. 2023 Apr;13(4):1554-1567. (PMID: 37139434)
Adv Sci (Weinh). 2023 Jan;10(2):e2202937. (PMID: 36453584)
Cancer Res. 2013 Jul 1;73(13):3927-37. (PMID: 23633481)
Cancer Cell. 2024 May 13;42(5):885-903.e4. (PMID: 38608702)
Nat Commun. 2022 Nov 25;13(1):7246. (PMID: 36433961)
Gut. 2023 Feb;72(2):345-359. (PMID: 35428659)
Angew Chem Int Ed Engl. 2021 Nov 8;60(46):24534-24542. (PMID: 34505339)
Cell Metab. 2023 Nov 7;35(11):1944-1960.e7. (PMID: 37898119)
Clin Cancer Res. 2010 Apr 15;16(8):2257-65. (PMID: 20371681)
Mol Cancer. 2024 Mar 8;23(1):48. (PMID: 38459558)
Gut. 2023 May;72(5):958-971. (PMID: 35688610)
Signal Transduct Target Ther. 2023 Jul 14;8(1):271. (PMID: 37443111)
Autophagy. 2024 Jun;20(6):1314-1334. (PMID: 38174993)
Cancer Cell. 2021 Apr 12;39(4):548-565.e6. (PMID: 33667385)
J Exp Med. 2017 Mar 6;214(3):579-596. (PMID: 28232471)
Natl Sci Rev. 2022 Nov 11;9(12):nwac250. (PMID: 36694802)
Sci Signal. 2020 May 05;13(630):. (PMID: 32371497)
Cell Rep Med. 2023 Sep 19;4(9):101162. (PMID: 37597521)
J Clin Oncol. 2007 May 20;25(15):1960-6. (PMID: 17452677)
Cancer Cell. 2020 Mar 16;37(3):289-307.e9. (PMID: 32183949)
Cell. 2023 Apr 13;186(8):1627-1651. (PMID: 36924769)
Cell. 2020 May 14;181(4):832-847.e18. (PMID: 32304665)
Gastroenterology. 2023 Oct;165(4):891-908.e14. (PMID: 37263303)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Cancer Discov. 2019 Aug;9(8):1102-1123. (PMID: 31197017)
Cell Discov. 2023 Jan 3;9(1):1. (PMID: 36596774)
Sci Adv. 2021 Dec 24;7(52):eabh2724. (PMID: 34936449)
Nat Commun. 2023 Sep 16;14(1):5758. (PMID: 37717006)
Cancer Cell. 2023 Sep 11;41(9):1606-1620.e8. (PMID: 37625401)
Nat Methods. 2024 Feb 26;:. (PMID: 38409223)
Nat Rev Clin Oncol. 2022 Dec;19(12):775-790. (PMID: 36216928)
Bioinformatics. 2019 Aug 15;35(16):2865-2867. (PMID: 30590489)
Nat Genet. 2022 Sep;54(9):1390-1405. (PMID: 35995947)
Cell Rep. 2022 Jan 25;38(4):110227. (PMID: 35081338)
Cancer Discov. 2020 Jul;10(7):1058-1077. (PMID: 32341020)
Cell Stem Cell. 2024 Jan 4;31(1):71-88.e8. (PMID: 38151022)
Gastroenterology. 2024 Jul;167(2):281-297. (PMID: 38492894)
Int J Mol Sci. 2020 Apr 20;21(8):. (PMID: 32326049)
Nat Commun. 2023 Aug 23;14(1):5123. (PMID: 37612267)
Cell Metab. 2022 Sep 6;34(9):1394-1409.e4. (PMID: 36070683)
Cell Death Dis. 2024 Apr 4;15(4):244. (PMID: 38575607)
Gut. 2023 Nov 24;72(12):2329-2343. (PMID: 37541772)
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):82. (PMID: 33437018)
Nature. 2023 Nov;623(7986):415-422. (PMID: 37914939)
Nat Cell Biol. 2024 Apr;26(4):613-627. (PMID: 38429478)
Cells. 2021 Feb 19;10(2):. (PMID: 33669751)
Nat Commun. 2019 Jan 16;10(1):254. (PMID: 30651550)
J Proteome Res. 2023 Dec 1;22(12):3703-3713. (PMID: 37983312)
Signal Transduct Target Ther. 2023 Mar 20;8(1):132. (PMID: 36941259)
Cell. 2023 Dec 21;186(26):5876-5891.e20. (PMID: 38134877)
Front Oncol. 2024 Apr 03;14:1283164. (PMID: 38634049)
Cancer Discov. 2022 Jun 2;12(6):1580-1597. (PMID: 35348629)
Clin Cancer Res. 2021 Feb 15;27(4):1082-1093. (PMID: 33188144)
Gut. 2022 Nov;71(11):2284-2299. (PMID: 35022267)
Nat Protoc. 2024 Jun;19(6):1679-1709. (PMID: 38504138)
Cancer Lett. 2023 Dec 1;578:216457. (PMID: 37865162)
J Clin Oncol. 2023 Oct 20;41(30):4714-4720. (PMID: 37847995)
Signal Transduct Target Ther. 2021 Feb 23;6(1):75. (PMID: 33619259)
Cancer Treat Rev. 2020 Jun;86:102017. (PMID: 32335505)
Nat Commun. 2018 Aug 23;9(1):3390. (PMID: 30139933)
Cancer Cell. 2024 May 13;42(5):869-884.e9. (PMID: 38579725)
Cancer Cell. 2023 Mar 13;41(3):374-403. (PMID: 36917948)
Diabetes Metab J. 2021 May;45(3):285-311. (PMID: 33775061)
Cell Death Dis. 2022 Jul 21;13(7):633. (PMID: 35864095)
Cancer Cell. 2009 Sep 8;16(3):183-94. (PMID: 19732719)
Nat Methods. 2024 Apr;21(4):623-634. (PMID: 38504113)
Gastroenterology. 2024 Jul;167(2):298-314. (PMID: 38467382)
Nat Biotechnol. 2020 Mar;38(3):333-342. (PMID: 31932730)
J Proteomics. 2021 Feb 10;232:104042. (PMID: 33161165)
Nat Commun. 2018 May 23;9(1):2028. (PMID: 29795293)
Clin Cancer Res. 2023 Sep 1;29(17):3408-3417. (PMID: 37266563)
Cell Discov. 2023 Sep 15;9(1):95. (PMID: 37714834)
Nat Biotechnol. 2021 May;39(5):599-608. (PMID: 33462507)
Nat Commun. 2022 Apr 21;13(1):2169. (PMID: 35449156)
Cell Rep Med. 2023 Oct 17;4(10):101234. (PMID: 37852179)
Cell Res. 2019 Sep;29(9):725-738. (PMID: 31273297)
Cell Metab. 2023 Dec 5;35(12):2119-2135.e5. (PMID: 37913768)
Nat Commun. 2024 Jan 13;15(1):509. (PMID: 38218939)
Cell Metab. 2019 Jun 4;29(6):1390-1399.e6. (PMID: 30827862)
Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12. (PMID: 37236195)
Nat Immunol. 2023 Sep;24(9):1443-1457. (PMID: 37563309)
Nat Protoc. 2021 Jun;16(6):2749-2764. (PMID: 34031612)
Nature. 2021 Feb;590(7847):642-648. (PMID: 33536616)
Cell. 2017 Dec 14;171(7):1611-1624.e24. (PMID: 29198524)
Gut. 2023 Aug;72(8):1510-1522. (PMID: 36759154)
Adv Sci (Weinh). 2022 Mar;9(7):e2103029. (PMID: 35064757)
Science. 2022 May 13;376(6594):eabl5197. (PMID: 35549406)
EBioMedicine. 2021 Apr;66:103315. (PMID: 33819739)
Anal Chem. 2020 Mar 3;92(5):3913-3922. (PMID: 31992042)
Cancer Cell. 2023 Nov 13;41(11):1989-2005.e9. (PMID: 37802055)
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2119168119. (PMID: 35412885)
Nat Genet. 2024 Jun;56(6):1121-1133. (PMID: 38760638)
J Exp Clin Cancer Res. 2023 Aug 9;42(1):199. (PMID: 37553567)
Commun Biol. 2024 Apr 9;7(1):430. (PMID: 38594506)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Gut. 2023 Jun;72(6):1211-1219. (PMID: 36997301)
Nat Methods. 2024 Mar 25;:. (PMID: 38528186)
Nat Cancer. 2024 May;5(5):774-790. (PMID: 38355776)
NPJ Precis Oncol. 2024 May 20;8(1):109. (PMID: 38769374)
N Engl J Med. 2022 Jun 2;386(22):2112-2119. (PMID: 35648703)
EBioMedicine. 2022 Mar;77:103897. (PMID: 35231699)
Sci Adv. 2020 Jul 22;6(30):eaba2619. (PMID: 32832661)
Nature. 2023 Oct;622(7982):383-392. (PMID: 37731001)
Nat Methods. 2023 Aug;20(8):1237-1243. (PMID: 37429992)
Lab Invest. 2022 Nov;102(11):1170-1181. (PMID: 35922478)
Nat Commun. 2022 Apr 13;13(1):1985. (PMID: 35418199)
Genes (Basel). 2019 Jul 12;10(7):. (PMID: 31336988)
Nat Cancer. 2022 Apr;3(4):505-517. (PMID: 35469013)
Cell Rep. 2024 Jan 23;43(1):113613. (PMID: 38232734)
Gut. 2021 May;70(5):900-914. (PMID: 32826305)
Small. 2022 Nov;18(44):e2203114. (PMID: 36148846)
Gastroenterology. 2022 Feb;162(2):604-620.e20. (PMID: 34695382)
Nat Commun. 2023 Feb 13;14(1):797. (PMID: 36781852)
Int J Biol Sci. 2022 Jan 1;18(3):1220-1237. (PMID: 35173549)
J Allergy Clin Immunol. 2019 Apr;143(4):1348-1350. (PMID: 30639344)
Nat Cancer. 2023 Jan;4(1):62-80. (PMID: 36585453)
Nat Biotechnol. 2015 May;33(5):495-502. (PMID: 25867923)
Cancer Discov. 2023 Jun 2;13(6):1428-1453. (PMID: 36946782)
Nat Rev Cancer. 2023 Aug;23(8):544-564. (PMID: 37349410)

81772639, 81802475, 81972258 National Natural Science Foundation of China; 81772639, 81802475, 81972258 National Natural Science Foundation of China; 81772639, 81802475, 81972258 National Natural Science Foundation of China

Keywords: Multiomics; Pancreatic cancer; Single-cell; Tumor microenvironment

0 (Biomarkers, Tumor)

Date Created: 20240709 Date Completed: 20240710 Latest Revision: 20240712

20240712

PMC11232163

10.1186/s12943-024-02050-7

38982491